Adult CHD patients (International Classification of Diseases, 10th Revision (ICD-10) codes Q20-Q28) who underwent CABG (Current Procedural Terminology (CPT) codes 1006208, 1006217, 1006200) were divided into two cohorts: those with documented perioperative GLP-1 RA use, defined as use within three months prior to or one month after CABG (Anatomical Therapeutic Chemical (ATC) code A10BJ), and those with no documented GLP-1 RA use (control cohort). The gene discussed is GLP1R; the disease is coronary artery disorder.